Gujarat Themis Biosyn Ltd Reports Strong Performance in FY 2024-25 with Revenue of Rs. 150.8 Crores
Gujarat Themis Biosyn Ltd, a prominent player in the pharmaceutical industry, has reported a robust performance in the financial year 2024-25. The company recorded a revenue of Rs. 150.8 crores, with EBITDA and PAT standing at Rs. 68.8 crores and Rs. 48.8 crores respectively. Despite facing minor volatility in tenders and power disruptions due to monsoon, GTBL maintained its production levels at optimal utilization levels, thanks to healthy demand. The company is poised for significant growth, backed by its domain expertise, established capacities, and long-standing customer relationships. GTBL is currently executing a capex plan, which includes the commissioning of a new R&D facility, a dedicated API block, and additional fermentation capacity. These initiatives aim to expand GTBL's product portfolio and strengthen its presence in the value chain.
Key Highlights
- Revenue of Rs. 150.8 crores in FY 2024-25
- EBITDA and PAT at Rs. 68.8 crores and Rs. 48.8 crores respectively
- Despite challenges, production levels maintained at optimal utilization
- Capex plan in progress, including commissioning of new R&D facility and API block
- Additional fermentation capacity being created for scale-up of in-house molecules